Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FOXHIPECT4 neoadjuvant therapy with or without HIPEC for locally advanced colon cancer
2025-520471-29-00Phase 3Authorised
- Sponsor
- Fundación para la Investigación Biomédica de Córdoba
- Start
- May 2026
- Modality
- Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of mitomycin c, fluorouracil, capecitabine, folinic acid and oxaliplatin in colon adenocarcinoma and Rectosigmoid Adenocarcinoma (2 arms), sponsored by Fundación para la Investigación Biomédica de Córdoba. Primary endpoints: Disease-free survival and Disease-free survival probability at 3 years. Planned start May 2026; status: authorised.
02
Drugs
mitomycin cfluorouracilcapecitabinefolinic acidoxaliplatin
03
Conditions
colon adenocarcinomaRectosigmoid Adenocarcinoma
Beyond the preview
Go deeper on 2025-520471-29-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-520471-29-00.